Use of models to identify cost-effective interventions: Pertussis vaccination for pediatric health care workers

Pediatrics

Volumn 128, Issue 3, 2011, Pages

  Greer, Amy L ^a,b   Fisman, David N ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bordetella pertussis; Cost effectiveness; Diphtheria tetanus acellular pertussis vaccine; Hospital infections; Neonate

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE PERSONNEL; HEALTH PROGRAM; INFECTION RISK; LIFE EXPECTANCY; MARKOV MODEL; MATHEMATICAL MODEL; PERTUSSIS; PERTUSSIS VACCINATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; VACCINATION;

ADULT; ALLIED HEALTH PERSONNEL; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; INTENSIVE CARE UNITS, NEONATAL; LIFE EXPECTANCY; MALE; MARKOV CHAINS; OCCUPATIONAL DISEASES; ONTARIO; QUALITY-ADJUSTED LIFE YEARS; STOCHASTIC PROCESSES; WHOOPING COUGH;

EID: 80052364078     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0796     Document Type: Article

References (46)

1. Crowcroft N.S., Pebody R.G. Recent developments in pertussis. Lancet. 2006;367(9526):1926-1936 (Pubitemid 43831996)
2. Friedman D.S., Curtis R., Schauer S.L., et al. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol. 2004;25(11):967-973 (Pubitemid 39551219)
3. O'Brien J.A., Caro J.J. Hospitalization for pertussis: Profiles and case costs by age. BMC Infect Dis. 2005;5:57
4. Lee G.M., Murphy T.V., Lett S., et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007;32(3):186-193
5. Daskalaki I., Hennessey P., Hubler R., et al. Resource consumption in the infection control management of pertussis exposure among Healthcare workers in Pediatrics. Infect Control Hosp Epidemiol. 2007;28(4):412-417 (Pubitemid 46658053)
6. Weber D.J., Rutala W.A. Pertussis: A continuing hazard for healthcare facilities. Infect Control Hosp Epidemiol. 2001;22(12):736-740 (Pubitemid 34162508)
7. Baggett H.C., Duchin J.S., Shelton W., et al. Two Nosocomial pertussis outbreaks and their associated costs: King County, Washington, 2004. Infect Control Hosp Epidemiol. 2007;28(5):537-543 (Pubitemid 46814542)
8. Bassinet L., Matrat M., Njamkepo E., et al. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol. 2004;25(11):995-997 (Pubitemid 39551223)
9. Boulay B.R., Murray C.J., Ptak J., et al. An outbreak of pertussis in a hematologyoncology care unit: Implications for adult vaccination policy. Infect Control Hosp Epidemiol. 2006;27(1):92-95 (Pubitemid 46939761)
10. Pascual F.B., McCall C.L., McMurtray A., et al. Outbreak of pertussis among healthcare workers in a hospital surgical unit. Infect Control Hosp Epidemiol. 2006;27(6):546-552 (Pubitemid 44023388)
11. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34
12. National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9
13. Ward J.I., Cherry J.D., Chang S.J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555-1563 (Pubitemid 41434634)
14. Edwards K.M., Talbot T.R. The challenges of pertussis outbreaks in healthcare facilities: Is there a light at the end of the tunnel? Infect Control Hosp Epidemiol. 2006;27(6):537-540 (Pubitemid 44023386)
15. Greer A., Fisman D. Keeping vulnerable children safe from pertussis: Preventing nosocomial pertussis transmission in the neonatal intensive care unit (NICU). Infect Control Hosp Epidemiol. 2009;30(11):1084-1089
16. Healy C.M., Rench M.A., Castagnini L.A., Baker C.J. Postpartum immunization against pertussis in a high-risk population. Vaccine. 2009;27(41):5599-5602
17. Walter E.B., Allred N., Rowe-West B., et al. Cocooning infants: Tdap immunization for new parents in the pediatric office. Acad Pediatr. 2009;9(5):344-347
18. United States Department of Labor. Consumer price index. Available at: www.bls.gov/cpi. Accessed January 9, 2009
19. Tiwari T., Murphy T.V., Moran J.; National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep. 2005;54(RR-14):1-16
20. World Health Organization. Choosing Interventions that Are Cost Effective (WHO-CHOICE): Cost-effectiveness Thresholds. Available at: www.who.int/choice/ costs/CER-thresholds/en/index.html. Accessed December 16, 2009
21. Laupacis A., Feeny D., Detsky A., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481
22. Little S.E., Caughey A.B. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: A cost-effectiveness analysis. Am J Obstet Gynecol. 2005;193(3 pt 2):1274-1279 (Pubitemid 41285533)
23. Statistics Canada. Life expectancy at birth, by sex, by province. Available at: www40.statcan.ca/l01/cst01/health26-eng.htm. Accessed April 30, 2009
24. Statistics Canada. 2006 Census: Family portrait: continuity and change in Canadian families and households in 2006: national portrait: census families. Available at: www12.statcan.ca/census-recensement/2006/as-sa/97-553/p5-eng.cfm. Accessed April 30, 2009
25. Fenwick E., O'Brien B.J., Briggs A. Cost-effectiveness acceptability curves: Facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405-415 (Pubitemid 38660390)
26. Fenwick E., Claxton K., Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-787 (Pubitemid 34041389)
27. Barton G.R., Briggs A.H., Fenwick E.A.L. Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886-897
28. Coudeville L., Van Rie A., Getsios D., et al. Adult vaccination strategies for the control of pertussis in the United States: An economic evaluation including the dynamic population effects. PLoS One. 2009;4(7):e6284
29. Edmunds W.J., Medley G.F., Nokes D.J. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective. Stat Med. 1999;18(23):3263- 3282
30. Fisman D.N., Spain C.V., Salmon M.E., et al. The Philadelphia High-School STD Screening Program: Key insights from dynamic transmission modeling. Sex Transm Dis. 2008;35(11 Suppl):S61-S65
31. Shim E., Galvani A.P. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine. 2009;27(30):4025-4030
32. Halperin S.A., Smith B., Russell M., et al. Adult formulation of a 5 component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000;19(4):276-283 (Pubitemid 30213063)
33. Pichichero M.E., Rennels M.B., Edwards K.M., et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293(24):3003-3011 (Pubitemid 40965070)
34. Lee G.M., Riffelmann M., Von Konig C.H.W. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26(29-30):3673-3679
35. Top K.A., Halperin B.A., Baxendale D., et al. Pertussis immunization in paediatric healthcare workers: Knowledge, attitudes, beliefs, and behaviour. Vaccine. 2010;28(10):2169-2173
36. Sandora T.J., Pfoh E., Lee G.M. Adverse events after administration of tetanus-diphtheria-acellular pertussis vaccine to healthcare workers. Infect Control Hosp Epidemiol. 2009;30(4):389-391
37. Iskedjian M., Walker J.H., Hemels M.E.H. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine. 2004;22(31-32):4215-4227 (Pubitemid 39330343)
38. Rank C., Quinn H.E., McIntyre P.B. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J. 2009;28(2):152-153
39. Wei S.C., Tatti K., Cushing K., et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315-321
40. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making. 2003;23(1):76-82 (Pubitemid 36133362)
41. Calugar A., Ortega-Sanchez I.R., Tiwari T., et al. Nosocomial pertussis: Costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis. 2006;42(7):981-988
42. Canadian Institute for Health Information. Quarterly Progress Report, January 1 to March 31, 2006. Available at: http://secure.cihi.ca/cihiweb/en/ downloads/fy05-06-q4-report-e.pdf. Accessed April 29, 2009
43. Statistics Canada. Population and dwelling counts, for Canada, provinces and territories, and census divisions, 2006 and 2001 censuses: 100% data. Available at: www12.statcan.ca/english/census06/data/popdwell/Table.cfm?T= 702&PR=35&SR=1&S=3&O=D. Accessed April 30, 2009
44. Iskedjian M., Einarson T.R., O'Brien B.J., et al. Economic evaluation of a new acellular vaccine for pertussis in Canada. Pharmacoeconomics. 2001;19(5 pt 2):551-563 (Pubitemid 32488743)
45. Fryback D.G., Dasbach E.J., Klein R., et al. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89-102 (Pubitemid 23113445)
46. Waitzman N.J., Romano P.S., Scheffler R.M. Estimates of the economic costs of birth defects. Inquiry. 1994;31(2):188-205 (Pubitemid 24226070)